What are the current guidelines for the treatment of constipation (obstipation) in adults?

Current Guidelines for Adult Constipation Treatment

Start with polyethylene glycol (PEG) as first-line therapy for chronic idiopathic constipation in adults, and if over-the-counter agents fail, escalate to prescription secretagogues (linaclotide, plecanatide) or prucalopride, all of which have strong recommendations with moderate-quality evidence. 1

Treatment Algorithm

First-Line: Over-the-Counter Agents

Osmotic Laxatives (Preferred Initial Therapy)

• Polyethylene glycol (PEG): Strong recommendation with moderate evidence 1
  • Start as primary OTC agent
  • No duration limit for long-term use
  • Dose-dependent bloating and flatulence are common but manageable side effects
  • Begin at lower doses and titrate up as tolerated

Alternative OTC Options

• Fiber supplements: Conditional recommendation 1

  • Consider if PEG not tolerated
  • Bloating and flatulence may limit use
  • Start low, increase gradually

• Magnesium oxide: Conditional recommendation 1

  • Alternative osmotic option
  • Monitor in patients with renal impairment

• Lactulose: Conditional recommendation 1

  • Less preferred due to gas/bloating profile

Rescue/Short-Term Therapy

Stimulant Laxatives

• Bisacodyl or sodium picosulfate: Strong recommendation for short-term/rescue use 1

  • Short-term defined as ≤4 weeks daily use
  • Excellent for occasional use or rescue therapy combined with other agents
  • Common side effects: abdominal pain, cramping, diarrhea
  • Start at lower doses and increase as tolerated

• Senna: Conditional recommendation 1

  • Start at lower doses than studied in trials
  • Abdominal cramping more common at higher doses
  • Appropriate for rescue therapy

Second-Line: Prescription Agents (When OTC Fails)

Secretagogues (Strong Recommendations)

The 2023 AGA-ACG guidelines provide three strong recommendations with moderate evidence for prescription agents when patients don't respond to OTC therapy 1:

1. Linaclotide: Strong recommendation, moderate evidence 1

   • Use as replacement or adjunct to OTC agents
   • Studied for 12 weeks but no duration limit on label
   • Main side effect: diarrhea (may lead to discontinuation)

2. Plecanatide: Strong recommendation, moderate evidence 1

   • Use as replacement or adjunct to OTC agents
   • Studied for 12 weeks but no duration limit on label
   • Main side effect: diarrhea (may lead to discontinuation)

3. Prucalopride (5-HT4 agonist): Strong recommendation, moderate evidence 1

   • Use as replacement or adjunct to OTC agents
   • Studied for 4-24 weeks but no duration limit on label
   • Side effects: headache, abdominal pain, nausea, diarrhea

Alternative Prescription Agent

• Lubiprostone: Conditional recommendation, low evidence 1
  • Use as replacement or adjunct to OTC agents
  • Nausea is dose-dependent; reduced when taken with food and water
  • Studied for 4 weeks but no label duration limit

Key Implementation Points

Strength of Evidence Hierarchy The 2023 joint AGA-ACG guideline 1 represents the highest quality evidence available, using GRADE methodology to assess certainty. The strong recommendations (PEG, bisacodyl/sodium picosulfate, linaclotide, plecanatide, prucalopride) carry moderate evidence quality, meaning we are moderately confident the true effect is close to the estimate.

Common Pitfalls to Avoid

• Don't delay escalation to prescription agents if OTC therapy fails after adequate trial (typically 2-4 weeks)
• Don't use stimulant laxatives as monotherapy for chronic daily use—reserve for rescue or combine with other agents
• Don't start fiber supplements at full doses—titrate slowly to minimize bloating
• Don't forget to take lubiprostone with food to reduce nausea

Practical Dosing Strategy

• Start all agents at lower doses than maximum studied doses
• Titrate up based on response and tolerability
• Combination therapy (OTC + prescription) is explicitly supported for refractory cases
• No evidence-based duration limits exist for most agents despite short trial durations

Special Considerations While dietary approaches (fiber supplements, probiotics, kiwifruits, prunes, high-mineral water) have emerging evidence 2, 3, the primary pharmacological guideline 1 focuses on medication management as the core intervention for chronic idiopathic constipation requiring treatment beyond lifestyle modification.

The stepwise approach—starting with PEG, using stimulants for rescue, then escalating to prescription secretagogues or prokinetics—provides a clear, evidence-based pathway that prioritizes both efficacy and safety while maintaining quality of life.